

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except per share data)

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2021	2020	2021	2020
Grant and collaboration revenue	\$ 80	\$ 441	\$ 190	\$ 1,157
Operating expenses:				
Research and development	833	462	1,436	1,270
General and administrative	733	427	1,805	930
	<u>1,566</u>	<u>889</u>	<u>3,241</u>	<u>2,200</u>
Loss from operations	(1,486)	(448)	(3,051)	(1,043)
Other income (expense), net	172	(7)	174	(8)
Net loss	<u>\$ (1,314)</u>	<u>\$ (455)</u>	<u>\$ (2,877)</u>	<u>\$ (1,051)</u>
Loss per common share	<u>\$ (0.21)</u>	<u>\$ (0.66)</u>	<u>\$ (0.49)</u>	<u>\$ (2.27)</u>

Condensed Consolidated Balance Sheet Information
(amounts in thousands)

	June 30, 2021	Dec. 31, 2020
Assets:		
Cash and cash equivalents	\$ 19,539	\$ 9,884
Other current assets	118	351
Total current assets	<u>19,657</u>	<u>10,235</u>
Property and other assets, net	160	159
Total assets	<u>\$ 19,817</u>	<u>\$ 10,394</u>
Liabilities and stockholders' equity		
Total liabilities	\$ 359	\$ 825
Stockholders' equity	19,458	9,569
Total liabilities and stockholders' equity	<u>\$ 19,817</u>	<u>\$ 10,394</u>
Common Shares Outstanding	6,328	3,834